FDA Grants Exclusive Market Status to OSE Immunotherapeutics for Heart Transplant Drug

Nantes, Monday, 27 April 2026.
The FDA has granted OSE Immunotherapeutics lucrative Orphan Drug Designation for its heart transplant treatment, unlocking seven years of potential market exclusivity and significant developmental tax incentives.